Navigation Links
MAQUET Cardiovascular Awarded New Contract by Novation
Date:7/9/2009

WAYNE, N.J., July 9 /PRNewswire/ -- MAQUET Cardiovascular US Sales LLC announced today that it has signed a new contract with Novation, one of the health care industry's leading group purchasing organizations. Under the terms of this agreement, MAQUET Cardiovascular US Sales LLC will supply VHA Inc., University HealthSystem Consortium (UHC) and Provista customers with its Cardiac Assist counterpulsation system, including Datascope Intra-Aortic Balloon Pumps (IABP) and Catheters. Intra-aortic balloon counterpulsation therapy is used in situations when a heart's own cardiac output is insufficient to meet the oxygenation demands of the body, and additional mechanical support is necessary.

"MAQUET has a strong portfolio of cardiovascular patient care products, and we look forward to building on this foundation with Novation in the future," said Raoul Quintero, President and CEO, MAQUET Cardiovascular US Sales LLC. "We are also extremely pleased that Novation recognizes the value of our IABP products, and that the clinical benefits of this innovative technology can now be extended to more of the critically ill patients who need it most."

Improving patient care and quality of life are of utmost importance to MAQUET. As a global leader, MAQUET Cardiovascular offers comprehensive support to perfusionists, interventionalists, cardiac and vascular surgeons and their teams by providing on- as well as off-pump coronary artery bypass surgery solutions in addition to intra-aortic balloon pump therapy solutions.

With a focus on coronary artery bypass graft (CABG) surgery, MAQUET has expertise in extracorporeal circulation and integrates a system of oxygenators, catheters/cannulae, filtration and other advanced heart-lung machine components to optimize cardiopulmonary perfusion outcomes. Additionally, MAQUET offers the market leading VASOVIEW Endoscopic Vessel Harvesting system for saphenous vein graft retrieval, off-pump coronary artery bypass (OPCAB) systems such as the HEARTSTRING III anastomosis device, ACROBAT Stabilizers and Positioners, along with a wide range of HEMASHIELD surgical grafts and fabrics for vascular surgery.

MAQUET Cardiovascular US Sales LLC is a division of MAQUET Medical Systems, part of the publicly listed Swedish group of companies GETINGE AB., a company with over 2.8 billion US dollars in revenues (2008 fiscal year) and 12,800 employees worldwide. In 2008, MAQUET itself generated pro-forma revenues (including the acquisition of Datascope Corp.) of more than 1.4 billion US dollars. The company now has 5,000 employees in 34 international sales and service organizations, as well as a network of more than 200 sales representatives. MAQUET has 170 years of healthcare experience, and is committed to becoming "The Gold Standard" for therapeutic medical equipment across the globe. As a market leader, MAQUET offers innovative medical solutions from three divisions: Surgical Workplaces, Critical Care and Cardiovascular. www.maquet.com

About Novation

Founded in 1998, Novation is the leading health care contracting services company for more than 2,500 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 14,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 500 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $35 billion in 2008. For more information on Novation, visit www.novationco.com.


'/>"/>
SOURCE MAQUET Cardiovascular
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MAQUET opens North Americas first VARIOP prefabricated operating suite system
2. MAQUET Opens North Americas First VARIOP Prefabricated Operating Suite System, Allowing Space Reconfiguration in Hours, Less Disruption Than Traditional Construction
3. Terumo Corporation Announces Settlement of all Patent Litigation with Maquet Cardiovascular
4. R&J Public Relations Selected to Promote MAQUET Inc.s VARIOP Operating Room Suite in North America
5. MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems
6. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
7. MAQUET Cardiovascular Launches HEARTSTRING III Proximal Seal System for Coronary Artery Bypass Graft Surgery
8. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
9. ARJO / Getinge / Maquet Announces New West Coast Showroom Opening
10. Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease?
11. Police work undermines cardiovascular health, comparison to general population shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: